|
Having trouble viewing this email? View it as a Web page.
| If you have trouble reading this e-mail, please click here. |
 |
|
Recommendations and Reports
Volume 62, No. RR-7
September 20, 2013 |
|
|
|
|
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization
Practices — United States,
2013–2014 |
|
| |
|
This report updates the 2012 recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccines for the prevention and control of seasonal influenza. Routine annual influenza vaccination is recommended for all persons aged ≥6 months. For the 2013–14 influenza season, it is expected that trivalent live attenuated influenza vaccine (LAIV3) will be replaced by a quadrivalent LAIV formulation (LAIV4). Inactivated influenza vaccines (IIVs) will be available in both trivalent (IIV3) and quadrivalent (IIV4) formulations. Vaccine virus strains included in the 2013–14 U.S. trivalent influenza vaccines will be an A/California/7/2009 (H1N1)–like virus, an H3N2 virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011, and a B/Massachusetts/2/2012–like virus. Quadrivalent vaccines will include an additional influenza B virus strain, a B/Brisbane/60/2008–like virus, intended to ensure that both influenza B virus antigenic lineages (Victoria and Yamagata) are included in the vaccine. This information is intended for vaccination providers, immunization program personnel, and public
health personnel. |
|
 full text |
|
|
| |
Department of Health and Human Services
Centers for Disease Control and Prevention |
| This email was sent to list-cdc@xxxxxxxxxxx using GovDelivery, on behalf of: Centers for Disease Control and Prevention (CDC) · 1600 Clifton Rd · Atlanta, GA 30333 · 1-800-CDC-INFO (800-232-4636) |
 |
|
